Resources

Your links to the most up-to-date therapeutic information and support.

Clinical References

Here’s your one-stop source for viewing and downloading NOCITA® (bupivacaine liposome injectable suspension) white papers, recent clinical studies and more.

NOCITA Technical Monograph

The NOCITA®(bupivacaine liposome injectable suspension) technical monograph reviews current post-operative pain management approaches as well as the therapeutic overview of safety and efficacy of a newly FDA-approved long-acting local anesthetic.

Comprehensive bibliography included.

Download PDF >

Clinical Effectiveness Study and Results

Pilot, randomized, placebo-controlled clinical field study to evaluate the effectiveness of bupivacaine liposome injectable suspension for the provision of post-surgical analgesia in dogs undergoing stifle surgery published in BMC Veterinary Research. 

Download PDF >

An Extended Release Local Anesthetic: Potential for Future Use in Veterinary Surgical Patients

One of the most effective means of preventing the transduction and transmission of acute and perioperative pain is through the use of local anesthetics. This paper will review the use of local anesthetics, particularly bupivacaine, in dogs and cats, and introduce a new formulation of prolonged release bupivacaine that is in development for dogs and cats.

Download PDF >

Safety Evaluation of EXPAREL® (DepoFoam® Bupivacaine) Administered by Repeated Subcutaneous Injection in Rabbits and Dogs: Species Comparison

EXPAREL (bupivacaine extended-release liposome injection) (DepoFoam bupivacaine) is in development for prolonged postsurgical analgesia. Repeat-dose toxicity studies were conducted in rabbits and dogs to compare the potential local and systemic toxicities of EXPAREL and bupivacaine HCl (Bsol), and the reversibility of any effects.

Download PDF >

The Safety of Liposome Bupivacaine Following Various Routes of Administration in Animals

Local and/or regional analgesic techniques are principal components of many multimodal analgesic techniques. This report presents results from four preclinical studies evaluating safety and pharmacokinetics (PKs) of liposome bupivacaine following intravascular (intravenous [IV], intra-arterial [IA]), epidural, and intrathecal administration in dogs.

Download PDF >

In-Clinic Tools

Introducing NOCITA into your clinic as part of a multimodal approach to post-operative pain control has never been easier with these simple tools.

Pet Owner Information Sheet

Provides a brief overview of NOCITA and why the veterinarian used it for post-operative pain control.

Download PDF >

Surgical Worksheet

A resource that can be downloaded and printed to help guide consistent peri-operative practices.

Download PDF >

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

NOCITA is now available.

“We began using Nocita on patients undergoing cranial cruciate ligament stabilization surgeries and have been very pleased with the results.  The product is intuitive to use and we have observed nothing but positive effects for our patients post-operatively.  Specifically, these patients appear to bear more significant weight immediately post-op than usually expected, require very little rescue analgesia, and are willing to eat early in the recovery period which has allowed easy transition to oral medications.  Nocita has quickly become standard protocol for analgesia on our cruciate ligament stabilization procedures.” 

Veterinary Surgeon

Milwaukee WI

Other therapeutics from Aratana

ENTYCE logo

 

ENTYCE (capromorelin oral solution) provides appetite stimulation.

Inappetence in dogs is a serious problem. Recently-FDA-approved ENTYCE provides safe, effective appetite stimulation.

VIEW WEBSITE

 

 

 

 

 

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

GALLIPRANT logo

 

GALLIPRANT® (gapriprant tablets)
for the control of pain and inflammation associated with osteoarthritis in dogs.

GALLIPRANT is a first-in-class piprant and a non-COX-inhibiting prostaglandin receptor antagonist (PRA). It specifically blocks the EP4 receptor, the primary mediator of canine OA pain and inflammation, and does not inhibit the production of many housekeeping prostanoids that maintain homeostatic functions.1

1Kirkby Shaw K, Rausch-Derra L, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2016;2(1):3-9.


In co-promotion with Elanco

VIEW WEBSITE

 

 

IMPORTANT SAFETY INFORMATION: Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If GALLIPRANT is used long term, appropriate monitoring is recommended. Concomitant use of GALLIPRANT with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of GALLIPRANT has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Please see the full Prescribing Information for more detail.